Clinical Scorecard: CGM Linked to More Time in Range
At a Glance
| Category | Detail |
|---|---|
| Condition | Type 2 Diabetes with End-Stage Kidney Failure |
| Key Mechanisms | Real-time continuous glucose monitoring improves secondary measures of glycemic control. |
| Target Population | Patients aged 18 to 80 years with insulin-treated type 2 diabetes receiving maintenance hemodialysis. |
| Care Setting | Dialysis centers |
Key Highlights
- Real-time continuous glucose monitoring improved time in range from 55% to 63%.
- Mean glucose levels decreased from 188 mg/dL to 174 mg/dL with continuous monitoring.
- Time above 180 mg/dL decreased from 44% to 35% with continuous monitoring.
- No significant difference in time below 70 mg/dL between monitoring strategies.
- Hyperglycemic episodes remained common in both monitoring periods.
Guideline-Based Recommendations
Diagnosis
Management
- Use real-time continuous glucose monitoring for improved glycemic control in insulin-treated patients.
Monitoring & Follow-up
- Monitor glucose levels regularly, with emphasis on time in range and hyperglycemia.
Risks
- Increased level 1 hypoglycemic episodes during continuous glucose monitoring.
Patient & Prescribing Data
Insulin-treated patients with type 2 diabetes on maintenance hemodialysis.
Continuous glucose monitoring may enhance glycemic management.
Clinical Best Practices
- Educate patients on sensor trend arrows and glucose patterns.
- Encourage regular capillary testing alongside continuous monitoring.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
